Core Viewpoint - The company has approved a comprehensive credit and guarantee limit for 2025, seeking a total of 1.06 billion yuan in credit and an additional mutual guarantee limit not exceeding 570 million yuan [1] Group 1: Financial Actions - The company is applying for a comprehensive credit limit of 90 million yuan from Bank of Communications, with its subsidiary providing real estate valued at 100.57 million yuan as collateral [1] - As of the announcement date, the total external guarantee balance for the company and its subsidiaries is 237.84 million yuan, which accounts for 23.18% of the most recent audited net assets [1] Group 2: Financial Performance - For the period from January to September 2025, the company's revenue is reported at 457.38 million yuan, while the net profit stands at a loss of 97.79 million yuan [1]

Core Insights - The Chinese traditional medicine industry is experiencing increasing differentiation driven by deepening centralized procurement policies and industrial upgrades, with Huasheng Technology making strategic adjustments to optimize resource allocation [1] Group 1: Strategic "Subtraction" to Release Growth Momentum - Huasheng Technology is focusing on its core business by strategically divesting non-core assets, including the sale of a 5.4019% stake in Shanghai Lingkai Technology for 200 million yuan, which has already generated 184.4 million yuan in cash [2] - The company is also progressing with the planned divestiture of its steel structure business, reflecting management's commitment to concentrate resources on the more promising pharmaceutical sector [2] - Management has indicated a continued focus on reducing investments in non-core businesses, reinforcing its strategic emphasis on the traditional Chinese medicine and health industry [2] Group 2: Technological Foundations and Brand "Addition" to Build Competitive Moat - Huasheng Technology has established a significant intellectual property barrier, with 205 patents applied for or acquired, including 171 authorized patents and 4 international invention patents as of June 2025 [3] - The company has pioneered the use of fingerprint mapping technology for quality control in its Sanqi Tongshu capsules, addressing industry challenges related to traditional Chinese medicine's quality and efficacy [3] - The Sanqi Saponins raw material was recognized as the first traditional Chinese medicine extract standard in the 2018 German Pharmacopoeia, marking a significant achievement in international recognition of product quality [3] Group 3: Brand Development and Market Positioning - The approval of Sanqi Tongshu capsules as the first traditional Chinese medicine to receive secondary protection status by the National Medical Products Administration strengthens its market position [4] - The successful completion of ISO certifications (ISO9001, ISO14001, ISO45001) by June 2025 indicates an upgrade in standardized management levels, setting a new quality benchmark in the industry [4] - The funds recovered from divesting non-core assets will support Huasheng Technology's research and market expansion, while the orderly divestiture of the steel structure business optimizes overall resource allocation [4]

Group 1 - The company Huasheng Technology (SZ 000790) announced the resignation of its board secretary, Ning Luhong, due to personal reasons, effective immediately upon delivery of the resignation to the board, and this will not affect the normal operations of the company [1] - For the first half of 2025, Huasheng Technology's revenue composition is as follows: pharmaceutical industry accounts for 78.26%, health services for 17.99%, other businesses for 2.57%, construction steel structure for 1.06%, and medical devices for 0.12% [1] - As of the report date, Huasheng Technology has a market capitalization of 2.4 billion yuan [1]

证券代码：000790 证券简称：华神科技 公告编号：2025-053 根据《公司法》《深圳证券交易所股票上市规则》及《公司章程》等有关规 定，在公司董事会秘书空缺期间，由公司副总裁、财务总监李俊先生代为履行董 事会秘书职责，公司将尽快完成董事会秘书的聘任工作。 宁潞宏先生在担任公司董事会秘书期间勤勉尽责，恪尽职守。公司董事会对 宁潞宏先生任职期间为公司发展所做出的努力和贡献表示衷心感谢！ 特此公告。 成都华神科技集团股份有限公司 成都华神科技集团股份有限公司 关于公司董事会秘书辞职的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 成都华神科技集团股份有限公司（以下简称"公司"）董事会于近日收到公 司董事会秘书宁潞宏先生提交的书面辞职报告。因个人原因，宁潞宏先生申请辞 去公司董事会秘书职务，辞职申请自送达公司董事会之日起生效，其辞职不会影 响公司相关工作的正常运行。 截至本公告披露之日，宁潞宏先生未持有公司股份，亦不存在应当履行而未 履行的承诺事项。 董 事 会 二〇二五年十二月三十日 ...

证券日报网讯 12月16日晚间，华神科技发布公告称，公司第十三届董事会第二十七次会议审议通过 《关于出售参股子公司股权后终止相关业绩承诺及补偿义务的议案》《关于拟对外转让药品上市许可及 相关技术暨签署的议案》《关于提请召开2026年第一次临时股东会的议案》。 （文章来源：证券日报） ...

Core Viewpoint - Huasheng Technology (000790.SZ) announced a complex project collaboration involving the transfer of the "smokeless moxibustion stick" drug listing license and related technology to Sichuan Binjiang Pharmaceutical for 18 million yuan, while also investing 4.5556 million yuan to acquire a 10% stake in Shanghai Aixingcheng Technology [1][2] Group 1: Transaction Details - The transfer of the "smokeless moxibustion stick" license includes granting Sichuan Binjiang Pharmaceutical national distribution rights during the transfer period, with Huasheng continuing as the exclusive manufacturer post-transfer [1] - The transaction is subject to approval by the shareholders' meeting [1] Group 2: Financial Overview of Parties Involved - Sichuan Binjiang Pharmaceutical has total assets of 2.85 million yuan and a net asset deficit of 530,000 yuan as of September 2025, with a revenue of 170,000 yuan and a net loss of 710,000 yuan for the first three quarters [1] - Shanghai Aixingcheng Technology, established in October 2025, has total assets of 41 million yuan but has recorded a net loss of 2.5 million yuan without generating revenue as of December 3 [1] Group 3: Performance Commitments - The parties involved have committed to achieving non-recurring net profits of at least 30 million yuan, 40 million yuan, and 55 million yuan for the years 2026 to 2028, respectively [2] Group 4: Financial Performance of Huasheng Technology - For the first three quarters of 2025, Huasheng Technology reported a revenue of 457 million yuan, a year-on-year decline of 31.02%, and a net loss of 97.7853 million yuan, representing a year-on-year decline of 1804.21% [2]

证券日报网讯12月16日晚间，华神科技（000790）发布公告称，公司将于2026年1月5日召开2026年第一 次临时股东会。 ...

Group 1 - Company Chuangxin Data plans to purchase servers not exceeding 9 billion yuan to provide cloud computing services for clients [1] - Company CaiXun plans to jointly invest in a fund specifically for a humanoid robot company, contributing 5 million yuan [2] - Company JiuZhiYang confirms normal operations and no undisclosed significant matters [3] Group 2 - Company Aerospace Changfeng states it does not engage in commercial aerospace business [4] - Company Aerospace Engineering clarifies its main business does not involve commercial aerospace [5] - Company Aerospace Information reports its main products do not include commercial aerospace [6] Group 3 - Company Tianpu shares have increased by 486.07% since August 22, indicating significant trading risks [7] - Company BaiDa Group's stock price has risen by 46.44% in a short period, posing potential risks of decline [10] Group 4 - Company Haiyou New Materials plans to invest approximately 300 million yuan in a polymer special film production project in Chengdu [8] - Company Huasheng Technology intends to transfer production technology for 18 million yuan and invest in a related company [11] Group 5 - Company Wolong Nuclear Materials plans to invest up to 1.5 billion yuan to expand its production base [12] - Company Jidian plans to invest in a 100MW wind power project in Guangxi with a total investment of 564 million yuan [13] Group 6 - Company China Energy Construction announces the official operation of the first phase of the world's largest green hydrogen and ammonia project [15] - Company Silan Microelectronics has received approval for a 12-inch high-end analog integrated circuit chip production line project with an investment of 10 billion yuan [16] Group 7 - Company Jiangte Electric plans to contest the cancellation of mining rights for a lithium-containing mineral [17] - Company China General Nuclear Power has begun construction of the Ningde Unit 6 nuclear power project [19] Group 8 - Company China Pacific Insurance reports a 9.4% increase in premium income for its life insurance subsidiary [20] - Company Bozhong Precision Engineering sees a significant increase in orders for electric vehicle battery swap stations [21] Group 9 - Company Dekeli plans to reduce its holdings by up to 100,000 shares [22] - Company Action Education intends to repurchase shares worth 20 to 25 million yuan [23] Group 10 - Company Gansu Energy Chemical wins a 359 million yuan engineering project [26] - Company Huayou Cobalt signs a memorandum for the supply of 79,600 tons of ternary precursor products [28] - Company Zhongneng Electric and its subsidiaries win multiple projects totaling approximately 423 million yuan [29]

Core Viewpoint - Huasheng Technology (000790) announced the transfer of its "smokeless moxibustion stick market authorization rights and related technology" to Sichuan Binjiang Pharmaceutical Co., Ltd. for a total amount of 18 million yuan (including tax) [1] Group 1 - The transfer aims to optimize asset allocation and focus on core business areas [1] - The business scale of the smokeless moxibustion stick product has not significantly impacted the company's performance [1] - This collaboration is expected to revitalize the company's existing pharmaceutical resources, optimize product structure, and enhance asset operational efficiency [1] Group 2 - The recovery of funds from this transaction will support the company's core strategic development and subsequent resource integration [1] - The move is intended to further strengthen the company's competitive position in its main business [1]

Core Viewpoint - The company aims to enhance the efficiency of its intangible assets and focus on core areas to improve sustainable profitability through the transfer of drug marketing licenses and related technologies [1] Group 1: Asset Management - The company held the 27th meeting of the 13th Board of Directors on December 15, 2025, to approve the proposal for the external transfer of drug marketing licenses and related technologies [1] - The company and Huasheng Pharmaceutical Factory will sign a project cooperation agreement with a partner [1] Group 2: Financial Transactions - Huasheng Pharmaceutical Factory plans to transfer its production technology and marketing license for smokeless moxibustion sticks, valued at RMB 18 million (including tax), to Binjiang Pharmaceutical [1] - The company will invest RMB 4.555556 million to acquire a 10% stake in Shanghai Aixingcheng Technology Co., Ltd., which focuses on the operation and management of medicinal moxibustion-related products [1]